Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Waldenstrom Macroglobulinemia × acalabrutinib × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 19 Lymphoma, Mantle-Cell 9 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Lymphoma 2 Leukemia, B-Cell 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Lymphatic Diseases 1 Leukemia, Prolymphocytic 1 Leukemia 1 Heart Failure 1 Glioblastoma 1 Chromosome 17 deletion 1

Interventions

zanubrutinib 7 Rituximab 7 ibrutinib 4 venetoclax 3 ixazomib 3 pirtobrutinib 2 Specimen Handling 2 Prednisone 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 CT-P10 2 Bortezomib 2 Biopsy 2 talquetamab 1 fludarabine 1 brexucabtagene autoleucel 1 acalabrutinib 1 Vincristine 1 Valganciclovir 1 Valacyclovir 1 Therapeutics 1 Thalidomide 1 Sirolimus 1 Polymerase Chain Reaction 1 Pharmacogenomic Variants 1 Lenalidomide 1 Ganciclovir 1 Foscarnet 1 Flow Cytometry 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04624906 2026-02-04

BRAWM

Sunnybrook Health Sciences Centre

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡